The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

Millions of Americans fighting obesity faced a setback last month when the Trump administration declined to allow Medicare ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

As more doctors and patients turn to the latest weight-loss drugs, researchers are trying to figure out which drug is right ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

In secondary endpoints, 64.6% of participants using Zepbound saw 15% weight loss compared with 40.1% on Wegovy. And Zepbound participants saw their waists reduced by an average 7.2 in (18.4 cm), ...

Hims & Hers Health shows impressive operating leverage and a scalable business model, with massive growth potential from new ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.